This study looks at using a medicine called emicizumab to help people with acquired hemophilia A (AHA). AHA is a condition where your blood doesn’t clot properly, leading to too much bleeding. The study is phase II, meaning it's testing to see how well the medicine works and how safe it is. Participants will receive the medicine through a subcutaneous injection (a shot under the skin) weekly. For the first two days, the doses are higher to start things off. Doctors will check how often bleeding happens over 12 weeks. If bleeding doesn't improve, the treatment might continue for another 12 weeks. Some people won’t be able to join the study, like those with other serious health issues.

• The study lasts 12 weeks, but might extend to 24 weeks if needed.
• Participants receive weekly injections of emicizumab.
• There may be risks if you have other health problems or are pregnant.